KR102538866B1 - 리신 접합된 이뮤노글로불린 - Google Patents

리신 접합된 이뮤노글로불린 Download PDF

Info

Publication number
KR102538866B1
KR102538866B1 KR1020197000701A KR20197000701A KR102538866B1 KR 102538866 B1 KR102538866 B1 KR 102538866B1 KR 1020197000701 A KR1020197000701 A KR 1020197000701A KR 20197000701 A KR20197000701 A KR 20197000701A KR 102538866 B1 KR102538866 B1 KR 102538866B1
Authority
KR
South Korea
Prior art keywords
ser
val
delete delete
lys
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197000701A
Other languages
English (en)
Korean (ko)
Other versions
KR20190018159A (ko
Inventor
자레드 스피델
얼 알본
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59315675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102538866(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20190018159A publication Critical patent/KR20190018159A/ko
Application granted granted Critical
Publication of KR102538866B1 publication Critical patent/KR102538866B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197000701A 2016-06-10 2017-06-12 리신 접합된 이뮤노글로불린 Active KR102538866B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
US62/348,410 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Publications (2)

Publication Number Publication Date
KR20190018159A KR20190018159A (ko) 2019-02-21
KR102538866B1 true KR102538866B1 (ko) 2023-06-02

Family

ID=59315675

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000701A Active KR102538866B1 (ko) 2016-06-10 2017-06-12 리신 접합된 이뮤노글로불린

Country Status (21)

Country Link
US (2) US10941431B2 (enExample)
EP (1) EP3468614A1 (enExample)
JP (1) JP7041077B2 (enExample)
KR (1) KR102538866B1 (enExample)
CN (1) CN109475642B (enExample)
AU (1) AU2017279352B2 (enExample)
BR (1) BR112018075253A2 (enExample)
CA (1) CA3026991A1 (enExample)
CL (1) CL2021003383A1 (enExample)
CO (1) CO2018013314A2 (enExample)
IL (1) IL263329B (enExample)
JO (1) JOP20180118A1 (enExample)
MX (1) MX419566B (enExample)
MY (1) MY202858A (enExample)
NZ (1) NZ748605A (enExample)
PE (1) PE20190340A1 (enExample)
PH (1) PH12018502594A1 (enExample)
RU (2) RU2021136863A (enExample)
SG (1) SG11201810470XA (enExample)
UA (1) UA126799C2 (enExample)
WO (1) WO2017213267A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124622C2 (uk) 2015-12-18 2021-10-20 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'юговані імуноглобуліни з c-кінцевим лізином
WO2017213267A1 (en) 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins
KR20220017909A (ko) * 2019-05-09 2022-02-14 메뤼스 엔.페. 단백질 다량체화를 위한 변이체 도메인 및 그의 분리
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
US20230242671A1 (en) * 2020-03-25 2023-08-03 Eli Lilly And Company Multispecific binding proteins and methods of developing the same
MX2022014530A (es) 2020-05-20 2023-02-27 Janssen Biotech Inc Métodos para la conjugación específica del sitio de proteínas que contienen dominios fc glicosilados.
JP2023543801A (ja) * 2020-09-25 2023-10-18 エピバックス、インコーポレイテッド レトロインベルソ制御性ｔ細胞エピトープ
IL311070A (en) * 2021-08-27 2024-04-01 Janssen Biotech Inc Anti-PSMA antibodies and uses thereof
CN117164701A (zh) * 2022-12-27 2023-12-05 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
AU2024227808A1 (en) 2023-02-28 2025-07-31 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
US20240337664A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
WO2025020905A1 (zh) * 2023-07-26 2025-01-30 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284713A1 (en) 2012-11-09 2015-10-08 Innate Pharma Recognition tags for tgase-mediated conjugation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
US9676871B2 (en) * 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
EP3613755A1 (en) * 2013-07-11 2020-02-26 Novartis AG Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
EP3027224B1 (en) * 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
PL3134127T3 (pl) * 2014-04-25 2020-07-27 Rinat Neuroscience Corp. Koniugaty przeciwciało-lek o dużym ładunku leku
UA124622C2 (uk) * 2015-12-18 2021-10-20 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'юговані імуноглобуліни з c-кінцевим лізином
WO2017213267A1 (en) 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150284713A1 (en) 2012-11-09 2015-10-08 Innate Pharma Recognition tags for tgase-mediated conjugation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chem., 2008, Vol.19, pp.271-278

Also Published As

Publication number Publication date
CN109475642A (zh) 2019-03-15
RU2018145507A (ru) 2020-07-10
PH12018502594A1 (en) 2019-10-14
US11753669B2 (en) 2023-09-12
MY202858A (en) 2024-05-25
IL263329B (en) 2022-05-01
JOP20180118A1 (ar) 2019-01-30
RU2762939C2 (ru) 2021-12-24
US20210171998A1 (en) 2021-06-10
RU2021136863A (ru) 2022-02-01
US10941431B2 (en) 2021-03-09
IL263329A (en) 2018-12-31
JP7041077B2 (ja) 2022-03-23
UA126799C2 (uk) 2023-02-08
WO2017213267A1 (en) 2017-12-14
CO2018013314A2 (es) 2019-02-19
JP2019525897A (ja) 2019-09-12
KR20190018159A (ko) 2019-02-21
MX419566B (es) 2025-01-14
CL2021003383A1 (es) 2022-08-19
US20180044711A1 (en) 2018-02-15
BR112018075253A2 (pt) 2019-04-30
CA3026991A1 (en) 2017-12-14
RU2018145507A3 (enExample) 2020-10-15
PE20190340A1 (es) 2019-03-07
AU2017279352A1 (en) 2018-12-13
NZ748605A (en) 2023-05-26
MX2018015331A (es) 2019-08-16
AU2017279352B2 (en) 2024-07-25
EP3468614A1 (en) 2019-04-17
SG11201810470XA (en) 2018-12-28
CN109475642B (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
US12214050B2 (en) C-terminal lysine conjugated immunoglobulins
KR102538866B1 (ko) 리신 접합된 이뮤노글로불린
EP3795591B1 (en) Cys80 conjugated immunoglobulins
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
WO2025093562A1 (en) Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
AU2022269007A1 (en) Methods and compositions thereof for site-specific labeling of human igg by proximity-based sortase-mediated ligation
HK40046837A (en) Cys80 conjugated immunoglobulins
HK1252625B (en) Cys80 conjugated immunoglobulins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000